1-20 of 31
Simon T. Barry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Sigrid K. Fey, Arafath K. Najumudeen, Dale M. Watt, Laura M. Millett, Catriona A. Ford, Kathryn Gilroy, Rosalin J. Simpson, Kathy McLay, Rosanna Upstill-Goddard, David Chang, William Clark, Colin Nixon, Joanna L. Birch, Simon T. Barry, Jennifer P. Morton, Andrew D. Campbell, Owen J. Sansom
Journal: Cancer Research
Cancer Res (2025) 85 (2): 251–262.
https://doi.org/10.1158/0008-5472.CAN-23-2709
Published: 15 January 2025
View article titled, <em>KRAS</em> Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Open the PDF for <em>KRAS</em> Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition in another window
Includes: Supplementary data
Journal Articles

Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma

Catriona A. Ford, Dana Koludrovic, Patricia P. Centeno, Mona Foth, Elpida Tsonou, Nikola Vlahov, Nathalie Sphyris, Kathryn Gilroy, Courtney Bull, Colin Nixon, Bryan Serrels, Alison F. Munro, John C. Dawson, Neil O. Carragher, Valeria Pavet, David C. Hornigold, Philip D. Dunne, Julian Downward, Heidi C. Welch, Simon T. Barry, Owen J. Sansom, Andrew D. Campbell
Journal: Cancer Research
Cancer Res (2024)
https://doi.org/10.1158/0008-5472.CAN-23-2814
Published: 05 December 2024
View article titled, Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
Open the PDF for Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma in another window
Includes: Supplementary data
Journal Articles

Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer

Alissandra L. Hillis, Timothy D. Martin, Haley E. Manchester, Jenny Högström, Na Zhang, Emmalyn Lecky, Nina Kozlova, Jonah Lee, Nicole S. Persky, David E. Root, Myles Brown, Karen Cichowski, Stephen J. Elledge, Taru Muranen, David A. Fruman, Simon T. Barry, John G. Clohessy, Ralitsa R. Madsen, Alex Toker
Journal: Cancer Research
Cancer Res (2024) 84 (19): 3250–3266.
https://doi.org/10.1158/0008-5472.CAN-24-0970
Published: 01 October 2024
View article titled, Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Open the PDF for Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

Wael Traboulsi, Subhadip Kundu, Pankaj Gaur, Zainab Ramlaoui, Dareen Sarhan, Nour Shobaki, Jacob Lee, Nazli Jafarzadeh, Simon T. Barry, Viia E. Valge-Archer, Vivek Verma, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB339.
https://doi.org/10.1158/1538-7445.AM2023-LB339
Published: 14 April 2023
View article titled, Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response
Journal Articles

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Deanna A. Mele, Neil Grimster, Gayathri Bommakanti, Jason Shields, Lucas Morrill, Kathryn Giblin, Maryann SanMartin, Yanjun Wang, Minwei Ye, Iswarya KarapaReddy, Kun Song, Theresa Proia, Niresh Hariparsad, Ryan Richards, Nadia Luheshi, Simon T. Barry, Stephen Fawell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3453.
https://doi.org/10.1158/1538-7445.AM2023-3453
Published: 04 April 2023
View article titled, Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion
Journal Articles

Abstract A010: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Xu Zhou, Roma Kurilov, John P. Neoptolemos, Benedikt Brors, Kai Hu, Teresa Peccerella, Jing-Yu An, Stephanie Roessler, Katrin Pfütze, Angela Schulz, Stephan Wolf, Nicolas Hohmann, Ulrike Heger, Oliver Strobel, Simon T Barry, Christoph Springfeld, Christine Tjaden, Frank Bergmann, Markus Büchler, Thilo Hackert, Franco Fortunato, Peter Bailey
Journal: Cancer Research
Cancer Res (2022) 82 (22_Supplement): A010.
https://doi.org/10.1158/1538-7445.PANCA22-A010
Published: 15 November 2022
View article titled, Abstract A010: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Journal Articles

Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8+ T cells, enhances stem cell-like memory CD8+ T cells, and leads to strong anti-tumor activity

Pankaj Gaur, Vivek Verma, Mays Alreem Elayyan, Zainab Ramlaoui, Simon T. Barry, Viia E. Valge-Archer, Paul D. Smith, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4217.
https://doi.org/10.1158/1538-7445.AM2022-4217
Published: 15 June 2022
View article titled, Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8<sup>+</sup> T cells, enhances stem cell-like memory CD8<sup>+</sup> T cells, and leads to strong anti-tumor activity
Journal Articles

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Maneesh Singh, Laura Bradshaw, Laura B. Prickett, Griffin Matthew, Maryann San Martin, Noel Monks, Lisa Drew, Simon T. Barry, Corinne Reimer, Theresa Proia
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1813.
https://doi.org/10.1158/1538-7445.AM2021-1813
Published: 01 July 2021
View article titled, Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors
Journal Articles

Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Miriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, María L. Suárez-Solís, Luis C. Fernández, Enrique Carrillo-de-Santa-Pau, Natalia del Pozo, Jaime Martínez de Villarreal, Clément Meiller, Yves Allory, Yuna Blum, Christine Pirker, Balazs Hegedus, Simon T. Barry, Amancio Carnero, Walter Berger, Didier Jean, Francisco X. Real
Journal: Cancer Research
Cancer Res (2020) 80 (4): 843–856.
https://doi.org/10.1158/0008-5472.CAN-19-1633
Published: 14 February 2020
View article titled, Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Open the PDF for Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features in another window
Includes: Supplementary data
Journal Articles

Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

Larissa S. Carnevalli, Danielle Carrol, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Molly A. Taylor, Antonio Montoya, Adina Hughes, Matthew King, Teresa Klinowska, Simon T. Barry
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 100.
https://doi.org/10.1158/1538-7445.AM2019-100
Published: 01 July 2019
View article titled, Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models
Journal Articles

Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer

Charles Sinclair, Alexey S. Revenko, R B. Johnson, Alison Peter, Molly A. Taylor, Lisa A. Hettrick, Stephanie Klein, Anisha Solanki, Melissa Chapman, James Yates, Helen K. Angell, Andrew Watt, Danielle Gattis, Brett P. Monia, Simon T. Barry, Paul Lyne, Mark Edbrooke, Frederick Goldberg, A R. Macleod
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2713.
https://doi.org/10.1158/1538-7445.AM2019-2713
Published: 01 July 2019
View article titled, Abstract 2713: Discovery and characterization of AZD8701, a high affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer
Journal Articles

Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Vivek Verma, Shamim Ahmad, Peng Zeng, Mikayel Mkrtichyan, Simon T. Barry, Paul D. Smith, Paulo C. Rodriguez, John E. Janik, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4717.
https://doi.org/10.1158/1538-7445.AM2018-4717
Published: 01 July 2018
View article titled, Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody
Journal Articles

Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

Francesca Bizzaro, Alessia C. Marchetti, Alessandra Decio, Francesca Ricci, Mark J. O'Connor, Molly A. Taylor, Zhongwu Lai, Simon T. Barry, Maria R. Bani, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2816.
https://doi.org/10.1158/1538-7445.AM2018-2816
Published: 01 July 2018
View article titled, Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib
Journal Articles

Abstract 311: Development of AZD2811, an aurora kinase B inhibitor, incorporated into an AccurinTM nanoparticle for use in haematological and solid cancers

Susan Ashton, Nicholas Floch, Paula Taylor, Colin Howes, Doug Ferguson, Matthew Ling, Maureen Hattersley, Shenghua Wen, Kim Maratea, Adina Hughes, Sean Redmond, Wolfram Brugger, Simon Smith, Alexander MacDonald, Keith Parry, Howard Burris, Young-Ho Song, Jim Nolan, Elizabeth Pease, Simon T. Barry
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 311.
https://doi.org/10.1158/1538-7445.AM2017-311
Published: 01 July 2017
View article titled, Abstract 311: Development of AZD2811, an aurora kinase B inhibitor, incorporated into an Accurin<sup>TM</sup> nanoparticle for use in haematological and solid cancers
Journal Articles

Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC

Sabari Vallath, Claire Reader, Jennifer Morton, Owen Sansom, Jeff Evans, Andrew Biankin, Simon T. Barry, Hemant Kocher, John F. Marshall
Journal: Cancer Research
Cancer Res (2016) 76 (24_Supplement): B53.
https://doi.org/10.1158/1538-7445.PANCA16-B53
Published: 14 December 2016
View article titled, Abstract B53: The integrin αvβ6 is a promising therapeutic target for treating PDAC
Journal Articles

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

David R. Driscoll, Saadia A Karim, Makoto Sano, David M. Gay, Wright Jacob, Jun Yu, Yusuke Mizukami, Aarthi Gopinathan, Duncan I. Jodrell, T.R. Jeffry Evans, Nabeel Bardeesy, Michael N. Hall, Brian J. Quattrochi, David S. Klimstra, Simon T. Barry, Owen J. Sansom, Brian C. Lewis, Jennifer P. Morton
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (23): 6911–6923.
https://doi.org/10.1158/0008-5472.CAN-16-0810
Published: 30 November 2016
View article titled, mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Open the PDF for mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 4524: A preclinical PKPD modeling & simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents

Rhys DO Jones, Rajesh Odedra, James WT Yates, Pablo Morentin Gutierrez, Barry Davies, Kevin Hudson, Simon T. Barry
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4524.
https://doi.org/10.1158/1538-7445.AM2015-4524
Published: 01 August 2015
View article titled, Abstract 4524: A preclinical PKPD modeling &amp; simulation strategy: building a predictive model of dose, schedule and therapeutic index for small molecule targeted anticancer agents
Journal Articles

Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Urs Hancox, Urszula Polanska, James T. Lynch, Carol Lenaghan, Cath Trigwell, Oona Depuelch, Phillippa Dudley, Juliana Maynard, Lara Ward, Kevin Hudson, Jon Curwen, Francisco Cruzalegui, Stephen Green, Klinowska Teresa, Simon T. Barry
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4696.
https://doi.org/10.1158/1538-7445.AM2015-4696
Published: 01 August 2015
View article titled, Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors
Journal Articles

Abstract 4862: PredICT: a novel solution for capturing, assembling and combining in vivo data

Rhys DO Jones, Marie Cooke, James Hinchliffe, Justin Morley, Simon T. Barry
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4862.
https://doi.org/10.1158/1538-7445.AM2015-4862
Published: 01 August 2015
View article titled, Abstract 4862: PredICT: a novel solution for capturing, assembling and combining in vivo data